Galapagos (NASDAQ:GLPG) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

A number of other equities research analysts have also recently commented on the stock. ValuEngine cut shares of Galapagos from a “hold” rating to a “sell” rating in a report on Friday. BTIG Research reiterated a “buy” rating and set a $118.00 price target on shares of Galapagos in a report on Monday, November 20th. Stifel Nicolaus reiterated a “buy” rating and set a $120.00 price target on shares of Galapagos in a report on Sunday, October 29th. Zacks Investment Research upgraded shares of Galapagos from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Morgan Stanley restated an “overweight” rating and set a $123.00 price objective (up previously from $92.00) on shares of Galapagos in a research report on Friday, October 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $111.00.

Shares of Galapagos (NASDAQ:GLPG) opened at $87.25 on Friday. Galapagos has a fifty-two week low of $57.86 and a fifty-two week high of $104.12.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cookson Peirce & Co. Inc. raised its position in Galapagos by 0.7% in the second quarter. Cookson Peirce & Co. Inc. now owns 3,045 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 20 shares during the period. Macquarie Group Ltd. raised its position in shares of Galapagos by 1.7% during the 2nd quarter. Macquarie Group Ltd. now owns 9,238 shares of the biotechnology company’s stock valued at $707,000 after purchasing an additional 156 shares during the period. Bank of New York Mellon Corp raised its position in shares of Galapagos by 0.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 38,093 shares of the biotechnology company’s stock valued at $2,915,000 after purchasing an additional 173 shares during the period. Northern Trust Corp raised its position in shares of Galapagos by 2.9% during the 2nd quarter. Northern Trust Corp now owns 18,480 shares of the biotechnology company’s stock valued at $1,414,000 after purchasing an additional 524 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Galapagos by 18.8% during the 1st quarter. Bank of America Corp DE now owns 4,379 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 694 shares during the period. Institutional investors and hedge funds own 19.71% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Galapagos (GLPG) Rating Lowered to Strong Sell at BidaskClub” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/galapagos-glpg-rating-lowered-to-strong-sell-at-bidaskclub/1742782.html.

About Galapagos

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.